Press Room

DPI China 2024

Thursday, March 21, 2024
Thursday, March 21, 2024
Location: Hangzhou, China
DPI China_2024_Hovione

Looking for a complete One-Site Solution for your inhalation and nasal therapies? Meet Hovione at the 11st DPI China Technology Conference! Delivering solutions every breath of the way.

We live and breathe innovation for the successful delivery of your inhalation and nasal therapies.

Hovione offers customized high-performance APIs, particle engineering and formulation along with a full range of highly specialized, patented and innovative devices, all in one site.

Don’t miss the chance to speak with our Inhalation Experts. 

On March 21, our team is at the 11th DPI China Technology Conference ready to share how this integration on a single site can support your project.


"End-to-end Respiratory Drug Delivery Platforms", with João Ventura, Product Management Director, Business Management Products.

The presentation will provide a perspective on the status and outlook of respiratory drug delivery and address the most relevant platforms for end-to-end dry powder inhalation (DPI) development, as DPIs are the dosage form of choice for achieving superior delivery efficiency to patients.

This presentation will focus on advanced particle engineering technologies for manufacturing inhalation active pharmaceutical ingredients (APIs), new formulation development platforms, aiming to address the pharmacokinetics requirements of the target drug and indication, and device developments for maximum drug delivery efficiency for lung delivery. An integrated, end-to-end development approach will be presented designed to maximize drug delivery efficiency and safety and address a diversified array of diseases.


Schedule a meeting today.

Learn more about our Inhalation and Nasal offering.



Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at  


Continuous Tableting and the Road to Global Adoption

Mar 04, 2024